Harnessing Precision Medicine to Redefine Psychiatric Treatment

On this episode of Power to the Patients, we are joined by Amit Etkin, Founder & CEO of Alto Neuroscience and adjunct professor at Stanford, to explore how precision psychiatry is paving the way for more tailored approaches to mental health care. Amit discusses his journey from academia to founding Alto, the role of biomarkers in advancing treatment, and Alto's work on precision psychiatric medicines for MDD. Key Takeaways: - Precision Psychiatry in Practice: Amit shares how precision psychiatry applies biological insights, such as EEG biomarkers, to better understand and treat mental health conditions. While still emerging, these tools hold promise for improving care for patients. - Biomarkers and Individualized Treatment: EEG biomarkers are being used to study how individual brain activity can guide treatment choices. Amit explains how these data-driven methods could reduce the need for trial-and-error in psychiatry. - Amit’s Shift from Academia to Industry: Leaving a tenured position at Stanford, Amit founded Alto Neuroscience to create scalable solutions for unmet needs in psychiatry. He reflects on the challenges and rewards of translating science into real-world applications. - ALTO-300, Advancing MDD Treatment: ALTO-300 is being developed as an adjunctive therapy for major depressive disorder (MDD) in patients who haven’t responded to a first-line antidepressant. By using EEG biomarkers, Alto aims to identify patients most likely to benefit, potentially improving outcomes and speeding up recovery. - The Future of Precision Psychiatry: While precision psychiatry is still an evolving field, Amit emphasizes the importance of collaboration, rigorous testing, and scalable tools to make meaningful progress in mental health care.